SUMMARY We performed intracardiac electrophysiologic studies in 33 patients with recurrent ventricular tachycardia. Nineteen patients underwent one, 10 patients two, and four patients three serial electrophysiologic studies. Ventricular tachycardia was successfully induced in 83% of the patients, and pacing methods were successful in terminating tachycardia in 71% of the studies, although pacing-induced acceleration of ventricular tachycardia occurred at least once in 36% of the studies. Seventeen of the 33 patients (52%) required a total of 24 external direct current cardioversions during study.
CHRONIC RECURRENT VENTRICULAR tachycardia is a potentially life-threatening dysrhythmia which is associated with significant morbidity and is often recalcitrant to antiarrhythmic drug therapy."' 2 We have demonstrated that an aggressive therapeutic approach involving careful antiarrhythmic drug trials can produce symptomatic improvement in some patients. 3 However, such an approach is time-consuming, requiring multiple therapeutic trials and prolonged hospitalization. The period of delay until adequate therapy is established causes risk, inconvenience and significant expense to the patient.
In patients who have recurrent ventricular tachycardia it is often possible to initiate the arrhythmia in the catheterization laboratory by using electrodecatheter stimulation of the heart.4 10 While induction of supraventricular tachycardia has been used successfully to test antiarrhythmic drug efficacy,", 11 Abbreviations: M = male; F = female; VSD = ventricular septal defect; CAD = coronary artery disease; S/P = status post; MI = myocardial infarction; LVA = left ventricular aneurysm; LVAX = left ventricular aneurysmectomy; RHD = rheumatic valvular heart disease; AR = aortic regurgitation; IHSS = idiopathic hypertrophic subaortic stenosis; AVR -aortic valve replacement; CM = cardiomyopathy; VT = ventricular tachyeardia; CABG = coronary artery bypass graft; VF = ventricular fibrillation; prop = propranolol; quin = quinidine; proc = procainamide; DPH = diphenylhydantoin; lido -lidocaine; diso = disopyramide; Rx = therapy; Dx = diagnosis. §"None" indicates that VT was readily induced after drug therapy; "partial" indicates that VT could only be induced with great difficulty or that its duration was brief after drug therapy; "strong" indicates that VT could not be induced after therapy. **Spontaneous VT was so frequent that VT induction was not attempted until after drug infusion.
ttVT induction was not attempted, as the patient entered the study in continuous VT. (RVILV2 and RVILV2V3)
Isoproterenol administration with the above (iso)
V-overdrive with V2 and V2V3 extrastimulation
Atrial overdrive (A-od) Abbreviations: V1 = ventricular paced beat forming a basic ventricular drive rhythm; V2,V3,V4,V5 = premature paced ventricular beats, V2 after a spontaneous ventricular beat or a V1,V3 following V2, and V4 after V3, etc; V-asynchronous = regular ventricular stimuli at a cycle length slower than an underlying VT resulting in random diastolic scanning; V-overdrive = a regular ventricular-paced rhythm at a cycle length more rapid than an underlying, but less than 225 beats per minute; V-burst = a short run of 3-8 ventricular paced beats at a regular, rapid rate of greater than 226 beats/min. cardia, as listed and defined in table 5. During programmed ventricular extrastimulation, the V2 stimulus was brought progressively closer to V1 or the previous spontaneous QRS until the ventricular effective refractory period was reached (30 patients). The V2 stimulus was then positioned 5-20 msec outside the refractory period, and V3 was similarly varied (24 patients). In one patient V4 extrastimulation was used similarly. Several ventricular pacing cycle lengths were tested during V1, V2 . . . Vn stimulation. Rapid ventricular pacing to terminate ventricular tachycardia was considered overdrive pacing (V-OD) if more rapid than the underlying tachycardia but below 225 beats/min. Rapid runs of stimuli at rates from 226-600/min were termed "bursts" (V-bursts).
When isoproterenol was administered to enhance inducibility of ventricular tachycardia, it was given intravenously in a dose ranging from 1-5 ,ug/min by constant infusion in order to increase the sinus rate from 25 to 50%.
-When ventricular tachycardia was induced, the QRS morphology in leads I, aVF and V1 was compared with the morphology of the patient's spontaneous ventricular tachycardia previously recorded on 12 lead electrocardiographic tracings. In group 1 patients, no drugs were administered. This group has been included so that our analysis of the effectiveness and complications of ventricular tachycardia induction could be based upon as much data as possible. In group 2 patients, when possible, inducibility of ventricular tachycardia was first documented. If ventricular tachycardia could be reliably and repeatedly induced, a drug, chosen either empirically or on the basis of prior antiarrhythmic therapy, was administered intravenously, except in two patients (13 and 19) who were studied only to determine the efficacy of already established oral therapy. Drugs were administered as follows: Lidocaine was tested first because of its rapid distribution. One hundred to 250 mg were given by bolus injection, followed by continuous infusion of 2-4 mg/min. Quinidine was given by intravenous infusion in doses from 5-10 mg/kg at a maximum rate of 0.5 mg/kg/min. Procainamide was given in doses of 6-13 mg/kg, also at a maximum rate of 0.5 mg/kg/min. Propranolol was given by intravenous injection of 5-15 mg over 10 minutes. Diphenylhydantoin, 300 mg, was administered intravenously to one patient (27) over 10 minutes, and disopyramide, 300 mg, was given orally to one patient (22) during electrophysiologic study. In group 2 patients, after each of one or more drug administrations, inducibility of ventricular tachycardia was again tested. If tachycardia was no longer inducible after protracted testing, the study was terminated and the patient was begun on oral therapy with the effective drug. If lidocaine was the only effective drug, tocainide was used for oral therapy.
In group 3 patients, who underwent serial electrophysiologic study, the first study was carried out as described for group 2 patients. The second electrophysiologic study was performed to determine whether a drug that was found effective by intravenous administration on the first study was still prophylactic against induction of ventricular tachycardia when given orally. In four patients, a third study was required to arrive at effective prophylactic therapy as judged by intracardiac stimulation.
In those patients who received several intravenous antiarrhythmic drugs during study before a prophylactic effect was observed, we could not always be certain whether a single drug or combination of drugs was responsible for the effect. Blood samples for drug concentrations were drawn frequently during the intracardiac electrophysiologic studies and were obtained whenever a drug was found to be effective, or when ventricular tachycardia could still be initiated so that the possibility of antiarrhythmic efficacy resulting from adequate concentrations of drug combinations, rather than solely the last administered drug, could be considered. In addition, these samples provided subsequent documentation of the adequacy or inadequacy of intravenous doses and served as a guide for subsequent oral therapies. In conjunction with use of drug concentration data, the following protocol was followed to rule out antiarrhythmic efficacy by virtue of a combined drug effect: On repeat electrophysiologic study the single drug after which a prophylactic effect had appeared was given alone; if it was not effective orally, combinations including the single drug and others given during the initial study were retested for efficacy, and serum concentrations were again determined. Fourteen patients were placed on chronic oral therapy with drugs found prophylactic on intracardiac stimulation. Three patients were treated with drugs found to be ineffective on testing, two of them because no effective drug was found, and one because a drug we found to be non-prophylactic was preferred by the referring physician. Clinical follow-up was carried out in these 17 patients ( were not on antiarrhythmic drugs and was successful in eight (30%). Other methods were less effective. In two (cases 9 and 32) of five patients (9, 10, 12, 16 and 32) who were administered isoproterenol, ventricular tachycardia induction was facilitated.
Nonclinical Ventricular Tachycardia
During the course of the 51 electrophysiologic studies, 204 episodes of ventricular tachycardia were induced. One hundred seventy-three of these tachycardias were morphologically identical to the patients' documented, spontaneously occurring tachycardias. Thus, 31 episodes of nonclinical ventricular tachycardia were induced. These tachycardias showed both a difference in cycle length and a difference in QRS morphology from the spontaneous arrhythmias ( fig.  3 ). Nonclinical ventricular tachycardia was induced in five of the 31 patients (16%) in whom induction was attempted; and, by coincidence, these were all group 3 patients. In one patient (30), only nonclinical ventricular tachycardia could be induced in the initial study.
However, on the second study the clinical form was easily induced.
Termination of Ventricular Tachycardia
Pacing methods used to terminate ventricular tachycardia are listed in table 5. Termination of ventricular tachycardia by pacing was attempted in 28 studies and was successful at least once in 20 of the studies (7 1%). The most frequently used methods were V2, V2 V3, and V-burst. V-burst was by far the most effective method and was successful in 10 of the 16 patients (62%) and 13 of 21 studies (62%) in which it was used ( fig. 4A ). V-burst was used a total of 89 times in these patients and was effective 55 times (62%).
Induced Acceleration of Ventricular Tachycardia
During attempted termination by pacing, acceleration of ventricular tachycardia occurred in nine of the 28 studies (32%) in which ventricular tachycardia interruption was attempted. These accelerated rhythms invariably showed altered QRS morphology compared with the underlying ventricular tachycardia.
In most instances the accelerated forms of tachycardia were rapid enough to be associated with hemodynamic deterioration, in some 4B ). When V-burst successfully terminated ventricular tachycardia without sustained acceleration, brief periods of altered or accelerated ventricular tachycardia often followed V-burst and immediately preceded termination of the arrhythmia ( fig. 4C ). Vburst resulted in acceleration of ventricular tachycardia 10 times in seven of the 16 patients in whom it was used. The incidence of acceleration was 10 times in 89 applications of V-burst (11%). V2 and V2 V3 stimulation accounted for two additional instances of acceleration.
External Direct Current Cardioversion
Seventeen of the 33 patients (52%) required a total of 24 external direct current cardioversions during the course of electrophysiologic studies. One patient required three cardioversions and five patients required two. The rest were cardioverted only once. Cardioversion was used in 18 of the 51 electrophysiologic studies (35%). In 12 of 24 instances (50%) the reason for cardioversion was acceleration of ventricular tachycardia resulting from attempted termination of an episode of clinical (either spontaneous or induced) tachycardia. In the 12 other instances, cardioversion was required because the clinical form of ventricular tachycardia was hemodynamically unstable or could not be terminated.
Blood Pressure Changes
The ability to monitor arterial pressure instantaneously was found to be extremely useful, since in many cases the rate of induced tachycardia and the patient's mental status alone did not allow adequate assessment of the patient's hemodynamic state. Cuff measurement does not permit sufficiently rapid and frequent evaluation of the blood pressure. We noted a rather marked fall in blood pressure with the onset of most episodes of ventricular tachycardia. Within 3-10 seconds, however, the blood pressure rose significantly. In those cases in which this return toward normal blood pressure did not occur, immediate cardioversion was frequently required. The prophylactic effect of antiarrhythmic drugs against electrode-catheter induction of ventricular tachycardia was tested in groups 2 and 3 (patients 13-33) (tables 3 and 4). A prophylactically effective drug was found in 15 of these 21 patients (7 1%) ( fig. 1) . For group 3 patients, who underwent the most extensive electrophysiologic testing, effective drugs were found in 10 of 14 (7 1% CIRCULATION treated with the drug suggested to be effective by electrophysiologic testing. In nine of these patients, repeat intracardiac stimulation was performed after establishment of stable plasma drug concentrations. In all nine, the previously effective drug was again effective against induction of ventricular tachycardia. The maximum time required to select effective therapy by this method was six hospital days.
Clinical Follow-Up The 14 patients in whom prophylactic drugs were identified were followed up for an average of 8.1 months (range one to 33 months). An additional three patients (13, 27 and 32) were placed on antiarrhythmic drugs found to be ineffective by electrophysiologic testing, and they were also followed up (table 6) . Drugs found acutely effective continued to be effective throughout the follow-up period in all 14 patients. One patient (16) in whom propranolol was strongly effective during acute testing had only a partially effective experience with the drug. Patient 22 had a partial response during both acute testing and chronic followup. The other patients were completely protected against symptomatic or identifiable ventricular tachycardia throughout their follow-up. None of the patients were taken off their drug because it was considered a therapeutic failure by their physician.
Of the three patients who were treated with drugs that were found to be ineffective during acute testing, one has had a good therapeutic response (patient 27, fig. 2 This study demonstrates that if a drug exerts a prophylactic effect in the catheterization laboratory against previously inducible ventricular tachycardia, then it is likely that the drug will be effective during chronic oral therapy. We tested antiarrhythmic drug efficacy in 21 patients and found a prophylactic drug for 15 (71%).
In most patients, the effective drug was identified during the first electrophysiologic study. The maximum time for selection of effective therapy under this protocol was six days. Although we found effective drugs for 71% of patients, we had to determine whether prophylaxis against catheter-induced ventricular tachycardia implied chronic efficacy against spontaneously occurring ventricular tachycardia. In the present study, all patients who were placed on chronic oral therapy with an acutely prophylactic drug experienced long-term control of ventricular tachycardia.
A theoretical problem arises when more than one drug is tested during a single electrophysiologic study, as it might be difficult to distinguish between antiarrhythmic efficacy due to a single drug or to the combination of that drug plus previously administered agents. In practice, this was not a significant problem. Most antiarrhythmic drugs given as brief intravenous loads without maintenance infusions dissipate rapidly, so initially high therapeutic concentrations are not sustained.
The alternative to this process would be to give each drug on a separate day, with control tachycardia induction studies before drug administration, thereby guaranteeing a single drug efficacy trial during each study. This approach should be taken when feasible. However, in those patients with frequent daily recurrences of life-threatening tachycardia requiring repeated cardioversion, a slow, strictly-controlled approach seems unjustified. In addition, inducibility of ventricular tachycardia after a drug is given intravenously does serve as a control for immediate administration of a second antiarrhythmic agent. Also, some patients will eventually respond only to drug combinations, having failed all single-drug trials; a method which includes multiple drug trials in a single study will permit more rapid identification of effective combinations of antiarrhythmic agents. Finally, the protracted hospitalization and increased cost of the one-drug-per-day method might offset many of the advantages of this new technique of assessing drug efficacy. Therefore, we feel that testing of only one drug every one or two days theoretically reduces the risk of making an erroneous drug selection, but that our method of multiple-drug testing is probably more rapid and can be used when prompt antiarrhythmic control is critical.
In all patients in whom sustained ventricular tachycardia occurred spontaneously or was induced, we attempted to terminate tachycardia by various pacing maneuvers. A short run of rapid stimuli (V-burst) was the best method for terminating ventricular tachycardia. This technique has been used by others,9 and was recently used for chronic termination of tachycardia by means of permanent pacing systems capable of administering short, rapid bursts of ventricular stimuli.'3 Fisher and associates9, 3 have suggested that bursts of rapid stimulation do not frequently cause degeneration of ventricular tachycardia to more rapid or unstable rhythms. They noted acceleration in only 4% of applications of V-burst (although acceleration was seen at least once in 43% of their patients). However, we found this complication of very rapid pacing more frequently. Josephson and coworkers'0 were much more successful in terminating ventricular tachycardia with V2, V2 V3 and V-asynchronous than we were. This may be due to differences in patient characteristics.
We used an arterial catheter to monitor each of ventricular tachycardia, we repeated electrophysiologic studies in nine patients on oral therapy with drugs previously found to be effective against induced ventricular tachycardia after intravenous administration. In all nine of these subjects the drug was again found prophylactic. While it seems likely that some degree of variability in ventricular tachycardia inducibility does occur, the degree of this variability and its impact upon this form of testing are unknown.
During our studies we induced nonclinical forms of ventricular tachycardia in 31 of 204 episodes of induced ventricular tachycardia. We saw this phenomenon in 15% of the patients. Thus, in order to draw meaningful conclusions from ventricular tachycardia induction studies, it is very important to compare induced arrhythmias with spontaneously occurring arrhythmias. Some patients may show multiple forms of induced ventricular tachycardia, only one of which resembles the spontaneous tachycardia ( fig. 2) . The significance of these nonclinical forms of ventricular tachycardia is uncertain. They may indicate that some patients have multiple reentry circuits, only one (or perhaps more) of which function clinically. If the latter were true, the site of extrastimulation (either the position of the electrode catheter or the site of origination of spontaneous premature ventricular beats) might be an important determinant of the form of ventricular tachycardia induced. In addition, nonclinical ventricular tachycardias may result from alternate pathway or "aberrant" conduction of impulses arising from the same locus responsible for the clinical form of tachycardia. Finally, it is possible that protracted ambulatory monitoring in these patients might have demonstrated the spontaneous occurrence of these nonclinical tachycardias.
We conclude from these studies that ventricular tachycardia can be induced by intracardiac stimulation in the majority of patients with chronic recurrent ventricular tachycardia in whom recent myocardial infarction has not occurred. In addition, testing of antiarrhythmic drug prophylaxis during intracardiac electrophysiologic study appears to be a frequently successful and accurate method for selecting effective antiarrhythmic drugs for chronic oral therapy. Whether this method offers an advantage (in terms of morbidity and mortality, duration of effective therapy, promptness of arriving at effective therapy, and expense to the patient) over noninvasive empirical methods of drug selection has not been determined.
